Medicare Confirms Coverage for Post-Transplant Monitoring Tests

Medicare confirmed the coverage of post-transplant rejection surveillance tests. Patients can benefit from blood tests like AlloSure^®, AlloMap^® and HeartCare^® to monitor their transplants and get earlier warning if there are indications of rejection.

What changed?

In August, Medicare issued a press release rolling back its proposed coverage restrictions for noninvasive lab tests for transplant monitoring. The announcement followed a fifteen-month campaign spearheaded by a broad group of transplant patient advocacy groups, physician societies, and individual patients and healthcare providers to advocate for the importance of patient access to these non-invasive tests.

To learn more about post-transplant monitoring tests, CLICK HERE.

VTS-PRO-10276-v1 Effective 12-2024